Drug Profile
Carbon-11-PF 06809247
Alternative Names: [11C]PF-06809247Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Pfizer
- Class Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Inflammation(Diagnosis) in USA (IV, Injection)
- 10 Mar 2017 Pfizer completes a phase I trial for Neuroinflammation (Diagnosis) in USA (IV) (NCT03100136)
- 16 Nov 2016 Phase-I clinical trials in Inflammation (Diagnosis) in USA (IV) (NCT03100136)